Kiniksa to Hold Third-Quarter Results Call on October 27 as Investors Await Update
Key Facts
Kiniksa Pharmaceuticals will hold its third-quarter 2026 results call on October 27 at 8:30 a.m. Eastern time, according to the company’s investor events calendar. The call comes after its shares, trading under the ticker KNSA, closed at $72.98 on October 26. Analyst estimates published ahead of the results pointed to earnings of $0.37 per share and revenue of $259.65 million for the quarter ended in September. Those forecasts put annual earnings growth at 62% and revenue growth at 44%. The call is the next opportunity for investors to review the company’s performance and compare it with those estimates.
Available trading data show the stock closed at $76.73 on October 23, before ending the October 26 session at $72.98. The two available closing prices provide context for tracking the shares ahead of the results call. The available data do not include a daily high or low for October 26. An initial draft attributed specific earnings-per-share and revenue figures to the third quarter, but those numbers are not supported by an open source in the information available here. The pre-release analyst estimates and the company’s earlier disclosures therefore remain the available financial context ahead of the call.
In the second quarter of 2026, Kiniksa reported total revenue of $243.6 million, compared with $156.8 million in the same period of 2025, according to its financial statement. Net income was $25.4 million, versus $17.8 million a year earlier. Net product revenue from ARCALYST was $243.6 million in the quarter, up about 55% year over year, the company said. Those prior results provide a backdrop for comparison with the third quarter, but are not reported figures for that quarter. The September estimates of $259.65 million in revenue and $0.37 per share were analyst forecasts issued before the results.
On July 28, the company raised its 2026 net revenue forecast for ARCALYST to a range of $980 million to $995 million, from a previous range of $930 million to $945 million. Chief Executive Officer Sanj Patel linked second-quarter growth to an increase in new and repeat prescribers of the drug for recurrent pericarditis, saying it had led to a "meaningful increase in the number of patients receiving treatment." By the end of the second quarter, about 21% of a group of 14,000 patients with recurrent pericarditis were receiving ARCALYST. More than 5,000 prescribers had also written prescriptions for the drug to treat the condition since its launch, the company said. These commercial indicators provide context for the company’s raised annual forecast.
Kiniksa said it had about $525.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, with no debt. That financial position is another second-quarter result available to investors as they follow the third-quarter report, alongside revenue, net income and the trajectory of ARCALYST sales. Actual results for the quarter ended in September and their details remain the focus of the call scheduled for October 27. It is set for 8:30 a.m. Eastern time, according to the company’s calendar.